{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-22-000059","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.315250+00:00","generated_at":"2026-06-24T01:05:34.448600+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LianBio Q2 net loss $42.4M; cash $349.4M; mavacamten China Phase 3 enrollment complete","bullets":["Net loss of $42.4M in Q2 2022 vs. $100.4M loss in Q2 2021; R&D expenses fell to $28.6M.","Cash balance $349.4M at June 30, 2022; runway projected into second half of 2024.","Completed enrollment in China Phase 3 EXPLORER-CN trial of mavacamten; topline data mid-2023.","Submitted NDAs: mavacamten in Singapore (oHCM) and infigratinib in Hong Kong (cholangiocarcinoma).","Three additional registration-enabling programs (TP-03, NBTXR3, BBP-398) to begin in China by year-end 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-22-000059","json":"https://secwatch.observer/filing/0001831283-22-000059.json","markdown":"https://secwatch.observer/filing/0001831283-22-000059.md","text":"https://secwatch.observer/filing/0001831283-22-000059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000059/0001831283-22-000059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128322000059/lian-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:05:34.448600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}